Current eye research · 2026
Salidroside Reverses Experimental Myopia by Restoring Collagen I Homeostasis via Activation of the microRNA-203a-3p/Matrix Metalloproteinase-2 Axis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Qinglan, Wu Jiaqing, He Bihua, Wei Lijiao, Cheng Ziang, Sun Lingbo, Tang Yuanjing, Liu Baoyu, Xie Xiangyong
Аннотация
PURPOSE: High myopia is a leading cause of visual impairment and blindness, characterized by axial elongation of the eyeball and changes in the sclera, particularly remodeling of extracellular matrix components. Salidroside, a natural glycoside from Rhodiola crenulata, has anti-hypoxic, anti-inflammatory, and antioxidant properties. However, its role in myopia progression remains unclear. This study aimed to explore the effects of salidroside on scleral microRNA (miR)-203a-3p, matrix metalloproteinase (MMP)-2, and collagen I in a form-deprivation myopia rat model.
METHODS: Experimental myopia was induced in Sprague-Dawley rats through monocular form deprivation for four weeks. Rats were orally administered low, medium, or high doses of salidroside (10, 20, and 40 mg/kg/day) starting one week after form deprivation. The scleral levels of miR-203a-3p, MMP2, and collagen I were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting. A dual-luciferase reporter assay confirmed the interaction between miR-203a-3p and the 3'-untranslated region (UTR) of MMP2. Biometric parameters, including axial length and refractive error, were assessed to evaluate the therapeutic efficacy of salidroside.
RESULTS: Form deprivation led to significant changes in scleral molecular markers, including upregulation of MMP2 and downregulation of miR-203a-3p and collagen I. Salidroside treatment dose-dependently reversed these changes, restoring miR-203a-3p levels, inhibiting MMP2 expression, and promoting collagen I synthesis. The dual-luciferase assay confirmed direct targeting of MMP2 by miR-203a-3p. In biometric analyses, salidroside significantly reduced axial elongation and myopic refractive shift, demonstrating its potential to slow myopia progression. Co-treatment with a miR-203a-3p mimic and salidroside enhanced these effects, suggesting a synergistic relationship between miR-203a-3p and salidroside.
CONCLUSIONS: Salidroside exerts protective effects against high myopia progression by regulating the miR-203a-3p/MMP2 axis and enhancing collagen I synthesis. These findings position salidroside as a promising pharmacological candidate for myopia treatment, offering a novel therapeutic approach to mitigate structural changes associated with myopia progression.
METHODS: Experimental myopia was induced in Sprague-Dawley rats through monocular form deprivation for four weeks. Rats were orally administered low, medium, or high doses of salidroside (10, 20, and 40 mg/kg/day) starting one week after form deprivation. The scleral levels of miR-203a-3p, MMP2, and collagen I were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting. A dual-luciferase reporter assay confirmed the interaction between miR-203a-3p and the 3'-untranslated region (UTR) of MMP2. Biometric parameters, including axial length and refractive error, were assessed to evaluate the therapeutic efficacy of salidroside.
RESULTS: Form deprivation led to significant changes in scleral molecular markers, including upregulation of MMP2 and downregulation of miR-203a-3p and collagen I. Salidroside treatment dose-dependently reversed these changes, restoring miR-203a-3p levels, inhibiting MMP2 expression, and promoting collagen I synthesis. The dual-luciferase assay confirmed direct targeting of MMP2 by miR-203a-3p. In biometric analyses, salidroside significantly reduced axial elongation and myopic refractive shift, demonstrating its potential to slow myopia progression. Co-treatment with a miR-203a-3p mimic and salidroside enhanced these effects, suggesting a synergistic relationship between miR-203a-3p and salidroside.
CONCLUSIONS: Salidroside exerts protective effects against high myopia progression by regulating the miR-203a-3p/MMP2 axis and enhancing collagen I synthesis. These findings position salidroside as a promising pharmacological candidate for myopia treatment, offering a novel therapeutic approach to mitigate structural changes associated with myopia progression.